Omnicell, Inc. (OMCL): Price and Financial Metrics

Omnicell, Inc. (OMCL)

Today's Latest Price: $123.23 USD

2.81 (2.33%)

Updated Jan 22 4:00pm

Add OMCL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 77 in Medical - Services

See all "A" rated Strong Buy stocks

OMCL Stock Summary

  • OMCL's current price/earnings ratio is 134.38, which is higher than 93.12% of US stocks with positive earnings.
  • The price/operating cash flow metric for OMNICELL Inc is higher than 86.25% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 289.98%, OMNICELL Inc's debt growth rate surpasses 94.55% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to OMNICELL Inc, a group of peers worth examining would be SPSC, CARG, PRLB, ATRS, and DT.
  • Visit OMCL's SEC page to see the company's official filings. To visit the company's web site, go to

OMCL Stock Price Chart Interactive Chart >

Price chart for OMCL

OMCL Price/Volume Stats

Current price $123.23 52-week high $125.00
Prev. close $120.42 52-week low $54.24
Day low $119.52 Volume 272,000
Day high $123.35 Avg. volume 418,707
50-day MA $112.77 Dividend yield N/A
200-day MA $81.93 Market Cap 5.21B

Omnicell, Inc. (OMCL) Company Bio

Omnicell provides automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The company was founded in 1992 and is based in Mountain View, California.

OMCL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$123.23$22.4 -81%

We started the process of determining a valid price forecast for OMNICELL Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that OMNICELL Inc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for OMNICELL Inc ended up being:

  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 24.53% of the free cash flow producing stocks we're observing.
  • OMNICELL Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 9. This value is greater than just 23.65% stocks in the Technology sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

ESE, GPRO, PAYC, SITM, and TESS can be thought of as valuation peers to OMCL, in the sense that they are in the Technology sector and have a similar price forecast based on DCF valuation.

OMCL Latest News Stream

Event/Time News Detail
Loading, please wait...

OMCL Latest Social Stream

Loading social stream, please wait...

View Full OMCL Social Stream

Latest OMCL News From Around the Web

Below are the latest news stories about OMNICELL Inc that investors may wish to consider to help them evaluate OMCL as an investment opportunity.

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.

Yahoo | January 19, 2021

Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results

Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.

Yahoo | January 19, 2021

Looking for a Growth Stock? 3 Reasons Why Omnicell (OMCL) is a Solid Choice

Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Yahoo | January 18, 2021

NextGen (NXGN) Solution Acts as Financial Bridge Amid COVID-19

NextGen's (NXGN) cloud-based EHR platform, NextGen Office, enables specialty practices to improve their financial performance during the pandemic.

Yahoo | January 15, 2021

Omnicell's EnlivenHealth™ Reports Strong Customer Demand for New SaaS Technology Solution to Help Pharmacies Meet COVID-19 Vaccination Challenges

Omnicell's EnlivenHealth™ Reports Strong Customer Demand for New SaaS Technology Solution to Help Pharmacies Meet COVID-19 Vaccination Challenges

Yahoo | January 11, 2021

Read More 'OMCL' Stories Here

OMCL Price Returns

1-mo 3.83%
3-mo 45.89%
6-mo 85.90%
1-year 43.04%
3-year 137.44%
5-year 334.83%
YTD 2.67%
2020 46.87%
2019 33.44%
2018 26.27%
2017 43.07%
2016 9.07%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8301 seconds.